SecBot SecBot
SECBOTREPLAY Home › Report › ZTS

ZTS · A U.S

Zoetis Inc. · COURT-RULING filed Feb 26, 2026 at 19:00 ET

At the news

BEARISHIMPACT 6/10

COURT-RULING filed Feb 26, 2026 at 19:00 ET

A U.S. District Court in New Jersey denied Zoetis Inc.'s (ZTS) motion to amend its invalidity contentions in a patent infringement lawsuit brought by Epitopix LLC over SRP2 vaccine technology. The court ruled that Zoetis failed to act diligently in asserting new indefiniteness arguments nearly 20 months after its initial contentions, blocking the addition of last-minute defenses.

  • Zoetis Inc. (ZTS) lost its motion to amend invalidity contentions in a patent infringement case involving U.S. Patent No. 8,637,048 covering SRP2 vaccine technology.
  • The court denied Zoetis' attempt to introduce new indefiniteness arguments under 35 U.S.C. § 112, ruling the motion untimely and lacking good cause.
  • The claims at issue in the litigation are Claims 21, 22, 47, and 50 of the '048 patent, which expired in January 2022 but may still support damages for past infringement.
  • The court emphasized that Zoetis had access to the patent for years and could have raised these grammatical-based indefiniteness arguments earlier, calling the late attempt a litigation strategy, not diligence.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access